Company Description
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally.
It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.
The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names.
It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine.
The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010.
Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2003 |
| IPO Date | Sep 28, 2010 |
| Industry | Specialty Chemicals |
| Sector | Materials |
| Employees | 1,598 |
| CEO | John Melo |
Contact Details
Address: 5885 Hollis Street, Suite 100 Emeryville, California 94608 | |
| Phone | 510-450-0761 |
Stock Details
| Ticker Symbol | AMRSQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001365916 |
| Employer ID | 55-0856151 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| Hermanus Kieftenbeld | Interim Chief Executive Officer, Chief Financial Officer and Chief Administration Officer |
| Peter DeNardo | Senior Director of Investor Relations and Corporate Communications |
| Doris Choi | General Counsel and Secretary |
| Christine Ofori | Chief People Officer |
| Beth Baker Bannerman | Chief Engagement and Sustainability Officer |
| Daya Fields | President of Pipette and Purecane |
| Annie Tsong | Chief Product and Technology Strategy Officer |
| Philip J. Gund | Chief Restructuring Officer |
| Oreste Fieschi | President of Sweeteners and Ingredients |
| Catherine Gore | President of Biossance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 7, 2024 | 15-12G | Securities registration termination |
| May 7, 2024 | 8-K | Current Report |
| Apr 23, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 21, 2024 | EFFECT | Notice of Effectiveness |
| Feb 21, 2024 | EFFECT | Notice of Effectiveness |
| Feb 21, 2024 | EFFECT | Notice of Effectiveness |